Cargando…
Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes
Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294552/ https://www.ncbi.nlm.nih.gov/pubmed/30412052 http://dx.doi.org/10.7554/eLife.38519 |
_version_ | 1783380749746962432 |
---|---|
author | Balboa, Diego Saarimäki-Vire, Jonna Borshagovski, Daniel Survila, Mantas Lindholm, Päivi Galli, Emilia Eurola, Solja Ustinov, Jarkko Grym, Heli Huopio, Hanna Partanen, Juha Wartiovaara, Kirmo Otonkoski, Timo |
author_facet | Balboa, Diego Saarimäki-Vire, Jonna Borshagovski, Daniel Survila, Mantas Lindholm, Päivi Galli, Emilia Eurola, Solja Ustinov, Jarkko Grym, Heli Huopio, Hanna Partanen, Juha Wartiovaara, Kirmo Otonkoski, Timo |
author_sort | Balboa, Diego |
collection | PubMed |
description | Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development. |
format | Online Article Text |
id | pubmed-6294552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-62945522018-12-15 Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes Balboa, Diego Saarimäki-Vire, Jonna Borshagovski, Daniel Survila, Mantas Lindholm, Päivi Galli, Emilia Eurola, Solja Ustinov, Jarkko Grym, Heli Huopio, Hanna Partanen, Juha Wartiovaara, Kirmo Otonkoski, Timo eLife Stem Cells and Regenerative Medicine Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development. eLife Sciences Publications, Ltd 2018-11-09 /pmc/articles/PMC6294552/ /pubmed/30412052 http://dx.doi.org/10.7554/eLife.38519 Text en © 2018, Balboa et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Stem Cells and Regenerative Medicine Balboa, Diego Saarimäki-Vire, Jonna Borshagovski, Daniel Survila, Mantas Lindholm, Päivi Galli, Emilia Eurola, Solja Ustinov, Jarkko Grym, Heli Huopio, Hanna Partanen, Juha Wartiovaara, Kirmo Otonkoski, Timo Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title | Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title_full | Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title_fullStr | Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title_full_unstemmed | Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title_short | Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes |
title_sort | insulin mutations impair beta-cell development in a patient-derived ipsc model of neonatal diabetes |
topic | Stem Cells and Regenerative Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294552/ https://www.ncbi.nlm.nih.gov/pubmed/30412052 http://dx.doi.org/10.7554/eLife.38519 |
work_keys_str_mv | AT balboadiego insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT saarimakivirejonna insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT borshagovskidaniel insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT survilamantas insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT lindholmpaivi insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT galliemilia insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT eurolasolja insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT ustinovjarkko insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT grymheli insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT huopiohanna insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT partanenjuha insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT wartiovaarakirmo insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes AT otonkoskitimo insulinmutationsimpairbetacelldevelopmentinapatientderivedipscmodelofneonataldiabetes |